Shenzhen Capital Group

Zhiyan Zaowu is a company focused on the research and development (R&D) and application of AI synthetic biology technologies.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

Transcend Vivoscope is a biotechnology company that focuses on the development of advanced microscopy imaging products and solutions. Its high-resolution imaging systems are designed to meet the needs of healthcare providers, enabling them to create innovative tools for various applications, including 3D cell biology, neuroscience, developmental biology, and clinical medicine. By offering cutting-edge technology, Transcend Vivoscope aims to enhance the capabilities of healthcare professionals in their research and clinical practices.

Bio-Link is a drug development company founded in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, including the development and manufacturing of key process equipment and consumables. Bio-Link's offerings include technologies for vaccines, antibody drugs, cell therapy, gene therapy, and various biologics. The company focuses on upstream cell culture, disposable dispensing reservoirs, and downstream processes such as chromatography and ultrafiltration. By delivering innovative products and services, Bio-Link aims to enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, the company explores wearable technology solutions for elderly care, further diversifying its portfolio.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

Yantai Lannacheng Biotechnology is a biotech business that focuses on the building class I diagnosis and therapy integrated novel tumor nuclear medication research and development platform.and therapy integrated novel tumor nuclear medication research and development platform.

Salus BioMed is a biomedical company focused on advancing genetic sequencing technology and spatial omics products. It specializes in the development of a DNA sequencing platform that enhances the measurement of gene activity through high-definition spatial transcriptomics. This technology supports users in diagnosing and treating various diseases, positioning Salus BioMed at the forefront of innovation in genomic research and healthcare solutions.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Health Gene Technologies provides premium solutions for multiplexed nucleic acid detection. Based on the high-resolution Capillary Electrophoresis (CE) Platform, HGT has independently developed a series of nucleic acid testing products, established a set of matured clinical nucleic acid testing solutions. Health Gene Technologies provides complete testing solutions for forensic DNA samples. It includes reagents and equipment required in the entire laboratory process.

Synceres Biosciences is a developer of synthetic biology that utilizes microorganisms as cell factories to create innovative products. The company employs engineering principles to design and evolve gene combinations, gene regulation networks, and signal transduction pathways. This approach enables Synceres to provide clients with new functional pathways and enzymes, facilitating the production of various active ingredient products. By leveraging advanced techniques in synthetic biology, Synceres aims to deliver effective solutions across multiple applications.

Regend Therapeutics is a leading company in the field of human organ regenerative medicine, specializing in the development of stem cell therapy products. Its flagship product, REGEND001, is the world's first autologous stem cell preparation for treating respiratory diseases and has received approval from the State Food and Drug Administration. Regend Therapeutics is notable for being the first organization in China to be registered for conducting clinical research on stem cells, with its operations overseen by the National Health and Health Commission. The company is recognized as a key player in research and development by the Ministry of Science and Technology. Regend has achieved ISO9001:2008 quality management system certification, and its stem cell preparation complies with various national and international standards, including China Metrology Accreditation and the China Conformity Assessment Committee. All clinical programs are conducted in accordance with regulatory guidelines and are registered with the National Trial Global Database of the National Institutes of Health. The company's research focuses on solutions for interstitial lung disease, assisted reproduction, stem cell storage, and chronic obstructive pulmonary disease.

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.

Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Laekna Therapeutics is a clinical‑stage biotechnology company that develops novel therapies for oncology and liver disease. The company has built a comprehensive research and development platform that moves molecules from discovery to registration‑ready trials. It has initiated six clinical studies, including three multi‑regional trials targeting standard‑of‑care resistant cancers. Its lead product candidates are LAE002, an ATP‑competitive AKT inhibitor for ovarian cancer, and LAE001, a therapeutic agent for liver disease. Laekna also maintains a broader pipeline of 14 additional candidates.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine. Maijing Gene was established in 2015 and is based in Guangzhou, China.

Zhimeng Biopharma, established in 2017 and headquartered in Shanghai, China, specializes in developing innovative medicines for chronic hepatitis B (CHB) and related liver diseases. Its portfolio includes HBV capsid inhibitor (CB-001), HBsAg inhibitor, TLR8 agonist, OX-40 agonist, and KCNQ2/3 K+ channel opener for epilepsy. Additionally, Zhimeng is actively exploring novel small molecule drugs to address neurological conditions like epilepsy, pains, and strokes.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Zhiyi Pharmaceutics Inc., established in 2013 and based in Guangzhou, China, specializes in the research and development of next-generation probiotics (NGPs) and live biotherapeutics (LBPs). The company's product pipeline includes SK08, TP2, ZY19, and SK09, all targeted at treating gastrointestinal disorders. Zhiyi Pharmaceutics focuses on innovative drug discovery, with a particular emphasis on the development of its proprietary strain SK08, which is poised to enter clinical trials. The company aims to expand its research into the relationship between human microbiome and disease, including microbial culture groups and pathobionts research, as well as the identification and separation of new functional strains.

Teligene Ltd., established in 2011 and headquartered in Jiangsu, China, is a pharmaceutical research and development company specializing in the creation of small-molecule drugs for oncology. The company's senior management team, experienced in advanced drug development technologies, focuses on researching and developing innovative, targeted anti-tumor drugs with independent intellectual property rights.

Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine. Maijing Gene was established in 2015 and is based in Guangzhou, China.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Hornetcorn is a company dedicated to the research and development of tumor-specific immune cells and gene technologies, primarily serving the biotechnology sector. It specializes in advanced cell therapy techniques, including CAR-T, D-CTL, D-CIK, and ECIK. Hornetcorn's activities encompass clinical research and applications, as well as technical services, aimed at providing innovative treatment solutions for clients and patients facing cancer-related challenges. Through its focused efforts in cell technology, the company plays a significant role in advancing therapeutic options within the field of biotechnology.

Shenogen Pharma Group is a drug discovery and development company.

Knowgene is an online knowledge sharing platform focused on genetic science with the public.

BGI Tech Solutions Co., Ltd., founded in 2012 and headquartered in Shenzhen, China, is a leading provider of advanced life sciences technology and bioinformatics services. The company operates lab facilities in Hong Kong, Wuhan, and Sacramento, along with branch offices in various regions, including Europe, the Americas, and multiple cities in mainland China. BGI Tech's extensive service network spans over 100 countries and regions, collaborating with more than 10,000 organizations and 30,000 partners on a multitude of research projects, including significant international genome initiatives. The company specializes in a wide range of sequencing solutions, including genomics, transcriptomics, epigenomics, metagenomics, PDXomics, and single-cell sequencing, among others. Through its commitment to integrated omics platforms, BGI Tech aims to accelerate advancements in life sciences and address critical health, agricultural, energy, and environmental challenges, ultimately contributing to the betterment of society.

MicroPoint Bioscience, Inc. is a Chinese company focused on the research and development of biochips. It specializes in the manufacturing of point-of-care testing (POCT) equipment and biological diagnostic test reagent cards, primarily for medical applications. The company's Lab On a Chip product series leverages micro-electronic mechanical systems (MEMS) to offer advanced microfluidic bio-diagnostic testing solutions. These innovations facilitate early diagnosis and monitoring of critical health issues, including vascular diseases and tumors. MicroPoint Bioscience customizes its products and services to meet the needs of various sectors, including human health, environmental protection, food safety, and scientific research, thereby contributing to improved healthcare outcomes and operational efficiency in medical settings.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.

Salus BioMed is a biomedical company focused on advancing genetic sequencing technology and spatial omics products. It specializes in the development of a DNA sequencing platform that enhances the measurement of gene activity through high-definition spatial transcriptomics. This technology supports users in diagnosing and treating various diseases, positioning Salus BioMed at the forefront of innovation in genomic research and healthcare solutions.